News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
234 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37187)
2018 (39119)
2019 (51334)
2020 (57662)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37440)
2025 (33091)
2026 (27455)
Month
January (2434)
February (2867)
March (3030)
April (3117)
May (3356)
June (2726)
July (2287)
August (2491)
September (2814)
October (2333)
Day
1 (17)
2 (20)
5 (162)
6 (203)
7 (146)
8 (247)
9 (159)
12 (234)
13 (160)
14 (74)
15 (62)
16 (77)
19 (73)
20 (83)
21 (99)
22 (83)
23 (51)
26 (64)
27 (98)
28 (112)
29 (156)
30 (54)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
October
Day
1
2
5
6
7
8
9
12
13
14
15
16
19
20
21
22
23
26
27
28
29
30
FDA
6 FDA Decisions To Watch in Q1 2026
After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after being delayed from the fourth quarter last year.
January 12, 2026
·
8 min read
·
Tristan Manalac
Drug Development
Biopharma Momentum To Propel Rare Disease, Cancer, Neuro Forward in 2026
After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told
BioSpace
, with both rare and chronic diseases headlining investor and R&D interest as JPM26 kicks off.
January 12, 2026
·
6 min read
·
Heather McKenzie
Opinion
To Broaden Access to CAR Ts, Mitigate Their Side Effects
The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome limits the reach of these transformative cancer therapies.
January 12, 2026
·
4 min read
·
Teresa Whalen
Press Releases
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
January 12, 2026
·
6 min read
Press Releases
ACTG Launches IPACE-HIV to Study Frailty Intervention
January 12, 2026
·
3 min read
Press Releases
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
January 12, 2026
·
5 min read
Press Releases
Enhanced Genomics Appoints Dr Katerina Leftheris to Its Board of Directors
January 12, 2026
·
2 min read
Press Releases
Chai Discovery Announces Collaboration with Eli Lilly and Company to Accelerate Biologics Discovery
January 12, 2026
·
2 min read
Press Releases
City of Hope Appoints Veteran Life Sciences Leader Vanessa Almendro Navarro as Chief Commercialization Officer
January 12, 2026
·
4 min read
Press Releases
Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma: New Results from the eNRGy Trial Presented at ASCO GI
January 12, 2026
·
10 min read
1 of 24
Next
